Latest Articles

Publication Date
Bayer Aims To Broaden Mirena’s Use With Phase III Endometrial Hyperplasia Study - Citeline News & Insights

Bayer Aims To Broaden Mirena’s Use With Phase III Endometrial Hyperplasia Study Citeline News & Insights

Published: Dec. 4, 2025, 11:19 a.m.
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - BioSpace

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia BioSpace

Published: Dec. 3, 2025, 2:11 p.m.
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - sharewise.com

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia sharewise.com

Published: Dec. 3, 2025, 5:04 a.m.
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - Business Wire

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Business Wire

Published: Dec. 2, 2025, 1:05 p.m.
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia - Stock Titan

Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia Stock Titan

Published: Dec. 2, 2025, 1:05 p.m.
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia - MarketScreener

Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia MarketScreener

Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia - MarketScreener

Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia MarketScreener

Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia - Bayer

Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia Bayer

Published: Dec. 2, 2025, 7:30 a.m.
Bayer begins Phase III study with Mirena for nonatypical endometrial hyperplasia - Medical Dialogues

Bayer begins Phase III study with Mirena for nonatypical endometrial hyperplasia Medical Dialogues

Published: Dec. 2, 2025, 5 a.m.
A Risk-Stratified Model for Predicting Endometrial Atypical Hyperplasia and Cancer to Guide Biopsy Decisions in Asymptomatic Postmenopausal Women - Frontiers

A Risk-Stratified Model for Predicting Endometrial Atypical Hyperplasia and Cancer to Guide Biopsy Decisions in Asymptomatic Postmenopausal Women Frontiers

Published: Nov. 24, 2025, 8:22 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!